EMERGENCY SURGERY FOR ANAPLASTIC THYROID CARCINOMA: A NARROW BAND TYPE OF DECISION

  • Mara Carsote 1“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Endocrinology, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
  • Florica Șandru “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Dermatovenerology, Elias University Emergency Hospital, Bucharest, Romania
  • Anda Dumitrașcu Department of Radiology and Medical Imagery, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
  • Alexandra Ioana Trandafir “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Endocrinology, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
  • Ana-Maria Gheorghe “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Endocrinology, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
  • Oana-Claudia Sima “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Department of Endocrinology, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
  • Adrian Ciuche “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Thoracic Surgery Department, “Dr. Carol Davila” Central Military Emergency University Hospital, Bucharest, Romania
  • Claudiu Nistor “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & Thoracic Surgery Department, “Dr. Carol Davila” Central Military Emergency University Hospital, Bucharest, Romania
Keywords: surgery, thyroid cancer, hormone, emergency, thyroidectomy

Abstract

Anaplastic thyroid carcinoma represents the most aggressive type of thyroid malignancy that typically is found very rare (accounting less than 1-2 % of all thyroid cancers). At the moment of first recognition, the condition is already aggressive with distant and local metastases in 8-9 out of 10 patients, including the potential of developing (or already having) a compressive goiter at cervical and/or retrosternal level. Many of these cases stands of a prior differentiated thyroid carcinoma (a follicular or papillary form) that had suffered a so-called “late anaplastic shift” in subjects with incomplete resection or without previous thyroid removal of any kind (and even undiagnosed condition). Our objective is to introduce a two-patient case series with anaplastic carcinoma and associated conundrum of multidisciplinary decisions, both of them being senior ladies with an associated thyroid dysfunction. A compressive goiter might underline an anaplastic thyroid carcinoma. The presence of a newly detected hyperthyroidism interferes with the decision of an emergency thyroidectomy. Some patients display cytological traits of a differentiated thyroid carcinoma and anaplastic elements may be detected only later (after post-surgery pathological exam). The overall prognosis remains poor in these instances.

References

[1] E.T. Pavlidis, I.N. Galanis, T.E. Pavlidis. “Update on current diagnosis and management of anaplastic thyroid carcinoma” World J Clin Oncol. vol. 14, no. 12, pp. 570-83, 2023.
[2] S. Wächter, D.K. Bartsch, E. Maurer. “Personalized approach to anaplastic thyroid carcinoma” Chirurgie (Heidelb). 2023. doi: 10.1007/s00104-023-01993.
[3] L.J. Leandro-García, I. Landa. “Mechanistic Insights of Thyroid Cancer Progression” Endocrinology vol. 164, no. 9, pp. bqad118, 2023.
[4] F. Sandru, A. Petca, M.C. Dumitrascu, R.C. Petca, M. Carsote. „Peutz-Jeghers syndrome: skin manifestations and endocrine anomalies (Review)” Exp Ther Med. vol. 22, no. 6, pp. 1387, 2021.
[5] S. Hamidi, A. Maniakas. “Recent advances in anaplastic thyroid cancer management” Curr Opin Endocrinol Diabetes Obes. vol. 30, no. 5, pp. 259, 2023.
[6] Y. Xing, Y. Wang, X. Wu. “Radiotherapy combined with immunotherapy successfully treated one case of anaplastic thyroid cancer: A case report” Front Oncol. vol. 13, pp. 1125226, 2023.
[7] C. Wang, Y. Zhang. “Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas” Int J Nanomedicine. vol. 18, pp. 6037-58, 2023.
[8] Y. Tao, P. Li, C. Feng, Y. Cao. “New Insights into Immune Cells and Immunotherapy for Thyroid Cancer” Immunol Invest. vol. 52, no. 8, pp. 1039-64, 2023.
[9] I. Califano, A. Smulever, F. Jerkovich, F. Pitoia. “Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease” Rev Endocr Metab Disord. vol. 25, no. 1, pp. 123-47, 2024.
[10] M.A. Gouda, V. Subbiah. “Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors” Am Soc Clin Oncol Educ Book. vol. 43, pp. e404770, 2023.
[11] W. Li, Y. Li, J. Li, H. Pang. “Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer” Technol Cancer Res Treat. vol. 22, pp. 15330338231169870, 2023.
[12] K. Yuang, H. Al-Bahadili, A. Chang. “An Unexpected Finding of Poorly Differentiated Thyroid Carcinoma in a Toxic Thyroid Nodule” JCEM Case Rep. vol. 1, no. 3, pp. luad052, 2023.
[13] L. Fatula, R.A. Snyder. “Rare Presentation of Anaplastic Thyroid Cancer With Thyrotoxicosis” Am Surg. vol. 86, no. 5, pp. 516-8, 2020.
[14] H.G. Zalzal, J. Chung, J.A. Perini. “Remarkable Presentation: Anaplastic Thyroid Carcinoma Arising from Chronic Hyperthyroidism” Case Rep Endocrinol. pp. 7261264, 2018.
[15] Y. Ling, F. Xu, X. Xia, D. Dai, R. Sun, Z. Xie. “Vitamin D receptor regulates proliferation and differentiation of thyroid carcinoma via the E-cadherin-β-catenin complex” J Mol Endocrinol. vol. 68, no. 3, pp. 137-51, 2022.
[16] T. Zhang, L. He, W. Sun, Y. Qin, P. Zhang, H. Zhang. “1,25 Dihydroxyvitamin D3 enhances the susceptibility of anaplastic thyroid cancer cells to adriamycin induced apoptosis by increasing the generation of reactive oxygen species” Mol Med Rep. vol. 20, no. 3, pp. 2641-8, 2019.
[17] T. Lawler, S. Warren Andersen. “Serum 25-Hydroxyvitamin D and Cancer Risk: A Systematic Review of Mendelian Randomization Studies” Nutrients. vol. 15, no. 2, pp. 422, 2023.
[18] M.C. Dumitrascu, F. Sandru, M. Carsote, R.C. Petca, A.A. Gheorghisan-Galateanu, A. Petca, A. Valea. „Anorexia nervosa: COVID-19 pandemic period (Review)” Exp Ther Med. vol. 22, no. 2, pp. 804, 2021.
[19] K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark, A. Di Cristofano, R. Foote, T. Giordano, J. Kasperbauer, K. Newbold, Y.E, Nikiforov, G. Randolph, M.S. Rosenthal, A.M. Sawka, M. Shah, A. Shaha, R. Smallridge, C.K. Wong-Clark. “2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer” Thyroid. vol. 31, no. 3, pp. 337-86, 2021.
[20] M.F. Leitzmann, A. Brenner, S.C. Moore, C. Koebnick, Y. Park, A. Hollenbeck, A. Schatzkin, E. Ron. “Prospective study of body mass index, physical activity and thyroid cancer” Int J Cancer. vol. 126, no. 12, pp. 2947-56, 2010.
[21] J.M. Gómez-Sáez. “Current and Future Perspectives in Thyroid Carcinoma Treatment” Eur Endocrinol. vol. 9, no. 1, pp. 22-7, 2013.
[22] M. Kang, N.R. Kim, J.Y. Seok. “Non-papillary thyroid carcinoma diagnoses in The Bethesda System for Reporting Thyroid Cytopathology categories V and VI: An institutional experience” Ann Diagn Pathol. pp. 152263, 2023.
Published
2023-11-09
How to Cite
[1]
M. Carsote, “EMERGENCY SURGERY FOR ANAPLASTIC THYROID CARCINOMA: A NARROW BAND TYPE OF DECISION”, JSS, vol. 10, no. 4, Nov. 2023.